Clinical Trial Update: A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II) [Phase 2]

View source ↗

Summary

Phase 2 GRATITUDE II trial evaluating miricorilant for antipsychotic-induced weight gain in obese adults with schizophrenia; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Schizophrenia

Drugs mentioned

• Miricorilant (CORT118335)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Antipsychotic-induced Weight Gain (AIWG) | Phase 2 | Status: COMPLETED | Results posted: 2024-06-13